These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15563241)

  • 21. Preclinical evaluation of PNU-151774E as a novel anticonvulsant.
    Fariello RG; McArthur RA; Bonsignori A; Cervini MA; Maj R; Marrari P; Pevarello P; Wolf HH; Woodhead JW; White HS; Varasi M; Salvati P; Post C
    J Pharmacol Exp Ther; 1998 May; 285(2):397-403. PubMed ID: 9580576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
    Perez-Lloret S; Rascol O
    Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound.
    Salvati P; Maj R; Caccia C; Cervini MA; Fornaretto MG; Lamberti E; Pevarello P; Skeen GA; White HS; Wolf HH; Faravelli L; Mazzanti M; Mancinelli E; Varasi M; Fariello RG
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1151-9. PubMed ID: 10027853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safinamide: from molecular targets to a new anti-Parkinson drug.
    Caccia C; Maj R; Calabresi M; Maestroni S; Faravelli L; Curatolo L; Salvati P; Fariello RG
    Neurology; 2006 Oct; 67(7 Suppl 2):S18-23. PubMed ID: 17030736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
    Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
    Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safinamide.
    Fariello RG
    Neurotherapeutics; 2007 Jan; 4(1):110-6. PubMed ID: 17199024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safinamide in the treatment of Parkinson's disease.
    Müller T
    Neurodegener Dis Manag; 2020 Aug; 10(4):195-204. PubMed ID: 32648512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
    Müller T; Foley P
    Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of motor function in early Parkinson disease by safinamide.
    Stocchi F; Arnold G; Onofrj M; Kwiecinski H; Szczudlik A; Thomas A; Bonuccelli U; Van Dijk A; Cattaneo C; Sala P; Fariello RG;
    Neurology; 2004 Aug; 63(4):746-8. PubMed ID: 15326260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
    Stocchi F; Vacca L; Grassini P; De Pandis MF; Battaglia G; Cattaneo C; Fariello RG
    Neurology; 2006 Oct; 67(7 Suppl 2):S24-9. PubMed ID: 17030737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.
    Maj R; Fariello RG; Ukmar G; Varasi M; Pevarello P; McArthur RA; Salvati P
    Eur J Pharmacol; 1998 Oct; 359(1):27-32. PubMed ID: 9831289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
    Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
    Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.